GLP-1 & MetabolicExtensively StudiedFDA ApprovedS

Liraglutide

Victoza / Saxenda · GLP-1 receptor (GLP1R) agonism: stimulates glucose-dependent insulin secretion, inhibits glucagon, slows gastric emptying, reduces appetite; 97% sequence homology to native GLP-1 with C16 fatty acid for albumin binding

Last reviewed . First published . By the PeptIQ team.

Educational and observational reference only. Not medical advice. Community charts use live PeptIQ self-reports.

Studies cited
9
Research grade
S
Experience
100

Overall check-ins

Activity
92

Trackers & reports

Typical Dose

0.6–1.8 mg daily (Victoza); 0.6–3 mg daily (Saxenda)

Route

Injectable

Cycle

Continuous

Storage

2–8°C Refrigerated

What is Liraglutide?

Liraglutide (Victoza for T2D, Saxenda for obesity) is Novo Nordisk's FDA-approved once-daily injectable GLP-1 receptor agonist. SCALE obesity trial demonstrated 5–8% body weight reduction and significant HbA1c reduction. While largely superseded by once-weekly semaglutide and tirzepatide for weight loss, Liraglutide remains a cornerstone type 2 diabetes treatment and has a robust cardiovascular outcomes trial (LEADER) demonstrating cardiovascular risk reduction.

Mechanism of Action

GLP-1 receptor (GLP1R) agonism: stimulates glucose-dependent insulin secretion, inhibits glucagon, slows gastric emptying, reduces appetite; 97% sequence homology to native GLP-1 with C16 fatty acid for albumin binding

Target: GLP-1 receptor (GLP1R)

Research Indications

Weight LossMost Effective

Clinical trials demonstrate significant body weight reduction with sustained benefit

Blood Sugar ControlMost Effective

Improves glycemic control and A1C levels in type 2 diabetes

Cardiovascular HealthEffective

Associated with reduced cardiovascular events in high-risk patients

Metabolic SyndromeEffective

Addresses multiple components of metabolic syndrome simultaneously

Research Protocols

These are commonly discussed research protocols — not medical advice. Consult a healthcare provider before use.

GoalDoseFrequencyRoute
Starting DoseLow doseOnce weeklySubcutaneous injection
Maintenance DoseTitrated doseOnce weeklySubcutaneous injection

Peptide & Drug Interactions

Always consult your healthcare provider before combining with other compounds. Use our Interaction Checker for reference.

Other GLP-1 Agonists (e.g. Semaglutide + Tirzepatide)Avoid
InsulinMonitor
SulfonylureasMonitor
MetforminCompatible
SGLT2 InhibitorsCompatible
Oral ContraceptivesCaution
Warfarin / Blood ThinnersMonitor
NAD+Compatible

How to Reconstitute & Inject

Use bacteriostatic (BAC) water only. Avoid saline — may cause precipitation. Refrigerate and use within 28 days.

  1. 1

    Remove Liraglutide vial from refrigeration and allow to reach room temperature (15–20 minutes)

  2. 2

    Clean vial top with alcohol swab and allow to air dry completely

  3. 3

    Using a sterile syringe, draw the calculated volume of bacteriostatic water (BAC water)

  4. 4

    Inject BAC water slowly down the side of the vial — do not aim directly at the powder

  5. 5

    Gently swirl in circular motions — DO NOT shake vigorously as this degrades the peptide

  6. 6

    Allow 2–3 minutes for full dissolution — solution should be clear and colorless

  7. 7

    Draw calculated dose into an insulin syringe for subcutaneous injection

  8. 8

    Inject into abdomen, thigh, or upper arm. Rotate injection sites to prevent lipodystrophy

  9. 9

    Store reconstituted solution refrigerated (2–8°C) and use within 28 days

What to Expect

Week 1–2

Initial appetite suppression may begin. Mild GI effects (nausea, fullness) as your body adapts.

Week 2–4

Noticeable reduction in food cravings and portion sizes. Early weight changes begin.

Week 4–8

Significant appetite control and steady weight loss. Improved blood sugar if applicable.

Week 8–16

Substantial weight reduction and enhanced energy. Metabolic markers begin improving.

Week 16–24

Major weight loss milestone with cardiovascular benefits and improved lipid profiles.

Week 24+

Maximum clinical efficacy. Comprehensive metabolic improvements and sustained benefits.

Side Effects & Safety

  • Nausea (most common, typically dose-dependent and transient)
  • Diarrhea or constipation during dose escalation
  • Vomiting, especially when starting or increasing dose
  • Reduced appetite and early satiety
  • Injection site reactions (redness, bruising)
  • Fatigue, particularly in early weeks
  • Rare: Pancreatitis — discontinue immediately with severe abdominal pain
  • Rare: Thyroid C-cell effects (contraindicated with MEN2 or thyroid cancer history)
  • Rare: NAION (optic nerve damage that can cause sudden, painless, sometimes permanent vision loss in one eye). FDA required a class-wide label warning for approved GLP-1 medicines in November 2026; seek urgent care for sudden vision changes

FDA Status & Regulatory Info

Regulatory status

Source: Drugs@FDA

FDA Approved

Liraglutide (Victoza for T2D, Saxenda for obesity) is Novo Nordisk's FDA-approved once-daily injectable GLP-1 receptor agonist. SCALE obesity trial demonstrated 5–8% body weight reduction and significant HbA1c reduction. While largely superseded by once-weekly semaglutide and tirzepatide for weight loss, Liraglutide remains a cornerstone type 2 diabetes treatment and has a robust cardiovascular outcomes trial (LEADER) demonstrating cardiovascular risk reduction.

Rx Required: Yes
503A Ban: No
Telehealth: Available
Full FDA Status Tracker

Frequently Asked Questions

Community-reported data

The information below reflects self-reported experiences from PeptIQ app users. It is not clinical evidence and should not replace professional medical advice.

What 6 users report

Observational self-reports from live PeptIQ aggregates. Not clinical outcomes.

6 community reports

Overall experience

From check-in ratings — separate from side effects logged below. Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.

Favorable 100% · Mixed 0% · Unfavorable overall 0%

Most reported benefits

Benefits users selected when logging a favorable or mixed check-in.

Appetite
6

Self-reported dose per injection

Median bucket: 2+ mg · Most common: 2+ mg

Reports span 1 to ≥ 2 mg (open-ended top bucket)

1–2 mg
2
2+ mg
4

Anonymized self-reports from PeptIQ users — not prescribing guidance. Buckets group similar logged amounts; open-ended top buckets mean “at least” that dose.

Commonly stacked with

Share Your Experience

Rate Liraglutide in the PeptIQ app and help the community make informed decisions.

Research References (7)

Cited PubMed, trial registry, and label sources for education only. We do not control third-party content.

  1. FDA Drug Label

    SAXENDA (liraglutide) injection — Prescribing Information

    Novo Nordisk. FDA Drug Label. 2014

    Source
    Wiki study page →
  2. FDA Drug Label

    VICTOZA (liraglutide) injection — Prescribing Information

    Novo Nordisk. FDA Drug Label. 2010

    Source
    Wiki study page →
  3. PubMed

    Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes (LEADER trial)

    Marso SP, Daniels GH, Brown-Frandsen K, et al. N Engl J Med. 2016

    Source
    Wiki study page →
  4. PubMed

    A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management (SCALE)

    Pi-Sunyer X, Astrup A, Fujioka K, et al. N Engl J Med. 2015

    Source
    Wiki study page →
  5. PubMed

    Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight in Adults With Overweight or Obesity Without Diabetes: The STEP 8 Randomized Clinical Trial

    Rubino DM, Greenway FL, Khalid U, et al. JAMA. 2022

    Source
    Wiki study page →
  6. PubMed

    Efficacy and Safety of Liraglutide 3.0 mg in Individuals With Overweight or Obesity and Type 2 Diabetes Treated With Basal Insulin: The SCALE Insulin Randomized Controlled Trial

    Garvey WT, Birkenfeld AL, Dicker D, et al. Diabetes care. 2020

    Source
    Wiki study page →
  7. PubMed

    GLP-1 receptor agonist discontinuation and cardiovascular events and all-cause mortality in people with type 2 diabetes: a retrospective cohort study

    Ceriello A, Prattichizzo F, Lucisano G, et al. Lancet Reg Health Eur. 2026

    Source
    Wiki study page →

Wiki tools

Observational indexes and compare views for Liraglutide.

Often tracked with

Educational information only

This page is for educational reference. It is not medical or legal advice. PeptIQ does not sell peptides or list vendors. Consult the FDA and a licensed healthcare professional for current regulations and individualized guidance.

PeptIQ app

Log your Liraglutide protocol in PeptIQ

Turn this Liraglutide guide into a living protocol — doses, vials, and history in one place.

Track LiraglutideOpen web app

iOS, Android, and web

Ask PeptIQ

Two taps on our guided quiz, then keep going in iMessage with sources — not Instagram screenshots.

Start the quizOr try Peptide X Quiz →

Quick Facts

Half-Life
~13 hours
Target
GLP-1 receptor (GLP1R)
Route
Injectable
Availability
Pharmacy & Telehealth
Rx Required
Yes
503A Ban
No
Browse peptide education

Talk with a clinician

PeptIQ is education only. We do not sell peptides or list vendors. Discuss Liraglutide with a licensed healthcare provider — not medical advice, not a prescription.

Download PeptIQ

Wiki tools

Observational indexes and compare views for Liraglutide.

Often tracked with